Increased Dose Period:
If efficacy is judged as decreased in the screening period, TA-650 at 10 mg per kg body weight is administered on the day of TA-650 administration at the start (week 0) and at every 8 weeks up to week 32 in the increased dose period , respectively, as one dose by intravenous infusion slowly over at least 2 hours.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01680159?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
